13599-12-7

Basic information

• Product Name: 5-PHENYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: SALOR-INT L250031-1EA;5-PHENYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER;ETHYL 3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE;1H-pyrazole-5-carboxylic acid, 3-phenyl-, ethyl ester;Ethyl 3-phenylpyrazole-5-carboxylate
• CAS NO: 13599-12-7
• Molecular Formula: C₁₂H₁₂N₂O₂
• Molecular Weight: 216.24
• Mol File: 13599-12-7.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 427.9°C at 760 mmHg
• Flash Point: 212.6°C
• Appearance: /
• Density: 1.196g/cm³
• Vapor Pressure: 1.58E-07mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-PHENYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PHENYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(13599-12-7)
• EPA Substance Registry System: 5-PHENYL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(13599-12-7)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 13599-12-7(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C12H12N2O2/c1-2-16-12(15)11-8-10(13-14-11)9-6-4-3-5-7-9/h3-8H,2H2,1H3,(H,13,14)

Upstream product

• 64-17-5 ethanol 
• 1381932-39-3 ethyl 2-acetoxy-3-nitro-4-phenylbut-3-enoate 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 1666-17-7 benzaldehyde p-toluenesulfonylhydrazone 
• 140-88-5 ethyl acrylate 
• 88330-79-4 2-hydroxy-4-oxo-4-phenylbut-2-enoic acid ethyl ester 
• 6296-54-4 ethyl 2,4-dioxo-4-phenylbutyrate 
• 126580-12-9 ethyl styryldiazoacetate 
• 623-73-4 diazoacetic acid ethyl ester 
• 25944-64-3 diethyl (1-phenylethenyl)phosphonate 
• 122-78-1 phenylacetaldehyde 
• 98-86-2 acetophenone 
• 95-92-1 oxalic acid diethyl ester 
• 536-74-3 phenylacetylene 

Downstream Products

• 939377-23-8 5-phenyl-2-(2,2,2-trifluoro-ethyl)-2H-pyrazole-3-carboxylic acid ethyl ester 
• 618070-56-7 ethyl 1-(2-oxo-2-phenylethyl)-3-phenyl-1H-pyrazole-5-carboxylate 
• 1262202-51-6 C₂₀H₁₈N₂O₃ 
• 1610022-71-3 1-benzyl-N-hydroxy-3-phenyl-1H-pyrazole-5-carboxamide 
• 1610022-72-4 1-(4-(tert-butyl) benzyl)-N-hydroxy-3-phenyl-1H-pyrazole-5-carboxamide 
• 1610022-73-5 N-hydroxy-1-(4-nitrobenzyl)-3-phenyl-1H-pyrazole-5-carboxamide 
• 1571074-98-0 C₁₉H₁₇N₃O₄ 
• 1610022-74-6 1-((6-chloropyridin-3-yl)methyl)-N-hydroxy-3-phenyl-1H-pyrazole-5-carboxamide 
• 939377-22-7 5-phenyl-2-(2,2,2-trifluoro-ethyl)-2H-pyrazole-3-carboxylic acid 

Relevant articles and documents

One-pot synthesis of 3(5)-ethoxycarbonylpyrazoles

A one-pot synthesis of ethoxycarbonylpyrazoles 2a-e, by the cyclocondensation of β-alkoxyvinyl trichloromethyl ketones 1a-e with hydrazine hydrochloride under mild conditions, is reported. A study using compounds 1a-e with different substituents proved that these are versatile building blocks for the synthesis of pyrazole derivatives, having a 3(5)-ethoxycarbonyl substituent, in good yields (70-91%).

Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2′-hydroxy-3′-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxyla te

We synthesized a series of novel small molecules, ethyl 1-(2′-hydroxy-3′-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxyla te derivatives 3a-3o, by the reaction of ethyl 3-aryl-1H-pyrazole-5-carboxylate with 2-aryloxymethylepoxide in the presence of potassium c

Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson’s Disease

Tyrosinase is involved in the synthesis of neuromelanin in the substantia nigra, which is closely correlated with the pathogenesis of Parkinson’s disease. Herein, we identified S05014 (l-Tyr, IC50 = 6.25 ± 1.43 nM; l-Dopa, IC50 = 0.6

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

Hydroxamic Acid-Based Histone Deacetylase (HDAC) inhibitors bearing a pyrazole scaffold and a cinnamoyl linker

Genetic abnormalities have been conventionally considered as hallmarks of cancer. However, recent studies have demonstrated that epigenetic mechanisms are also implicated in the insurgence and development of cancer. Patterns of the epigenetic component in